The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT1 and dCK protein expression.
R. Maréchal
No relevant relationships to disclose
j. Bachet
No relevant relationships to disclose
J. R. Mackey
No relevant relationships to disclose
P. Demetter
No relevant relationships to disclose
K. Graham
No relevant relationships to disclose
A. Couvelard
No relevant relationships to disclose
M. Svrcek
No relevant relationships to disclose
A. Bardier
No relevant relationships to disclose
P. Hammel
No relevant relationships to disclose
A. Sauvanet
No relevant relationships to disclose
C. Louvet
No relevant relationships to disclose
F. Paye
No relevant relationships to disclose
P. Rougier
No relevant relationships to disclose
L. Hannoun
No relevant relationships to disclose
T. Andre
No relevant relationships to disclose
C. M. Dumontet
No relevant relationships to disclose
C. E. Cass
No relevant relationships to disclose
I. Salmon
No relevant relationships to disclose
J. Emile
No relevant relationships to disclose
J. Van Laethem
No relevant relationships to disclose